Senti Bio Secures Additional Financing from Leaps by Bayer and Provides Update on Proposed Business Combination with Dynamics Special Purpose Corp. (DYNS)
24 mai 2022 08h30 HE
|
Senti Biosciences, Inc.
- Leaps by Bayer led Series B investment in Senti Bio in 2021; Additional Convertible Note financing expands committed capital to PIPE investment associated with previously announced Business...
Senti Bio Highlights Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells in Three Presentations at ASGCT Annual Meeting
18 mai 2022 08h30 HE
|
Senti Biosciences, Inc.
- SENTI-202 oral presentation details systematic optimization of Logic Gating Gene Circuit technology in allogeneic CAR-NK cells to more precisely target tumor cells in acute myeloid leukemia, while...
Senti Bio to Present Data from Gene Circuit-Engineered Allogeneic CAR-NK Cell Therapy Pipeline at Upcoming Scientific Conferences
02 mai 2022 16h00 HE
|
Senti Bio
- Three ASGCT abstracts highlight new data related to application of gene circuit technology to enhance efficacy and safety of cancer-killing CAR-NK cells - - ISCT abstract describes scalable,...
Senti Bio to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
18 avr. 2022 09h00 HE
|
Senti Bio
SOUTH SAN FRANCISCO, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (“Senti Bio”), a leading Gene Circuit company today announced that co-founders Tim Lu, MD, PhD, Chief...
Senti Bio Presents New Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at AACR Annual Meeting
08 avr. 2022 13h00 HE
|
Senti Bio
- Preclinical data demonstrate the use of gene circuits to improve the therapeutic potential of allogeneic CAR-NK cells for the treatment of solid tumors - - CAR-NK cells armed with calibrated...
Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at AACR Annual Meeting
08 mars 2022 16h30 HE
|
Senti Bio
SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Senti Bio, a leading gene circuit company, today announced the acceptance of an abstract for presentation at the American Association...
Senti Bio to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
06 janv. 2022 08h02 HE
|
Senti Bio
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (“Senti Bio”), a leading Gene Circuit company today announced that Tim Lu, MD, PhD, Chief Executive Officer and...
Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Company Pioneering Gene Circuit-Engineered Cell and Gene Therapies
20 déc. 2021 07h05 HE
|
Senti Bio
- Business combination with Dynamics Special Purpose Corp. (Nasdaq: DYNS) is expected to provide more than $296 million in gross proceeds, over $153 million of which is fully committed in a common...
Senti Bio Highlights Preclinical Advances on Pipeline Candidate SENTI-202 at ASH 2021 Annual Meeting
13 déc. 2021 09h02 HE
|
Senti Bio
- Preclinical data demonstrates complete functionality of SENTI-202 OR+NOT Logic Gated gene circuits for the elimination of AML cancer cells while sparing healthy stem cells - - Presentation...
Senti Bio Highlights Colorectal Cancer Preclinical Data from Logic Gated CAR-NK Cell Program at 36th SITC Annual Meeting
12 nov. 2021 16h46 HE
|
Senti Bio
- SENTI-401 engineered to target colorectal cancer cells while sparing healthy cells - - Preclinical proof-of-concept data suggest that Logic Gated gene circuits can be used in CAR-NK cells to...